1123.1000 -49.50 (-4.22%)
NSE Sep 30, 2026 11:01 AM
Volume: 100.6K
 

1123.10
-4.22%
Geojit BNP Paribas
The company reiterated its $400mn revenue target for FY28, supported by over 60 pending low-competition U.S. launches, while management remains constructive on other regulated markets, where an expanding product portfolio and new customer additions are expected to drive stronger growth and eventually scale these markets to revenue levels comparable with the U.S. business....
Strides Pharma Scien.. has an average target of 1352.00 from 1 broker.
More from Strides Pharma Science Ltd.
Recommended